Early Trials of PRMT5 Inhibitors Leave Much to Be Desired, B

Despite the discovery of protein arginine methyltransferase 5 more than 20 years ago, interest in the potential oncogene as a treatment target for patients with hematologic and solid malignancies has increased in recent years with the advancement of multiple novel agents through preclinical and early-phase studies.

Related Keywords

United States , Denmark , Copenhagen , Køavn , American , Biomed Pharmacother , Ulrikn Lassen , Varun Monga , American Society Of Hematology Annual Meeting Exposition , University Of Copenhagen , American Society Of Clinical Oncology , American Association For Cancer Research Annual Meeting , Department Of Internal Medicine , Pfizer , Department Of Clinical Medicine , European Society For Medical Oncology Congress , University Of Iowa Carver College Medicine , Phase Studies , Display Mixed , Clinical Trials , Clinical Oncology , Annual Meeting , Hematology Annual Meeting , Medical Oncology Congress , Clinical Medicine , Data Show Promise , Effectively Targeting , Internal Medicine , Iowa Carver College , Iowa City , American Association , Cancer Research Annual Meeting , Cancer Gene , Clin Cancer , Protein Arginine Methyltransferase 5 , Patients With Hematologic And Solid Malignancies , D , The University Of Copenhagen ,